Earnings · US stocks
10x Genomics Inc Class A (TXG) earnings
10x Genomics Inc Class A published its quarterly report on 2026-11-05. The stock moved +8.34% in the 3 trading days after the report.
- Report
- quarterly report
- Published
- 2026-11-05
- Result
- Great
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | +2.10% | — |
| 3 days | +8.34% | — |
| 7 days | -5.29% | — |
Report history
Over the last 8 reports, EPS beat the consensus estimate in 7 of them. The stock rose in the 3 trading days after 7 of 8 reports (average +10.22%).
| Published | EPS YoY | EPS | EPS surprise | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|
| 2026-11-05 | — | 0.03 | +240.30% | +8.34% | — | — |
| 2026-08-06 | -93.80% | 0.03 | +258.37% | +28.25% | +67.98% | +68.88% |
| 2026-05-07 | — | 0.07 | +219.15% | -6.69% | +46.92% | +45.17% |
| 2026-02-12 | — | 0.07 | +276.25% | +11.76% | +11.25% | +18.18% |
| 2025-11-06 | — | -0.02 | +67.43% | +27.62% | +23.46% | +21.93% |
| 2025-08-07 | +4700.00% | 0.48 | +702.13% | +0.08% | +1.87% | -3.10% |
| 2025-05-08 | — | -0.10 | +64.90% | +11.82% | +25.03% | +18.82% |
| 2025-02-12 | -275.00% | -0.14 | -27.12% | +0.58% | -21.58% | -15.57% |
The last 8 reported quarters. Moves count trading days from the first tradeable session after the report; "30d vs index" is the excess return over the market index.
Stock valuations: TXG · Stock news: TXG
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.